OPB-171775

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameOPB-171775
Drug Alias NameOPB-171775
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPDE3A-SLFN12 protein complex formation inducers
TargetscGMP-inhibited 3',5'-cyclic phosphodiesterase ASchlafen family member 12
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOtsuka Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiodexa Pharmaceuticals PLCOtsuka Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A